RCM-1 |
Catalog No.GC33117 |
RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC50 of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 339163-65-4
Sample solution is provided at 25 µL, 10mM.
RCM-1 is a FOXM1 inhibitor.
RCM-1 inhibits cellular proliferation via increasing duration of cell cycle and mitosis in human and mouse cancer cell lines in vitro. Treatment with RCM-1 increases duration of mitosis and cell cycle in the cancer cell lines. RCM-1 inhibits colony formation of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits migration of cancer cells in vitro in a dose-dependent manner. RCM-1 inhibits the initiation as well as growth of cancer cell colonies in vitro[1].
RCM-1 treatment reduces growth of Rd76-9 rhabdomyosarcomas in mice. RCM-1 treatment decreases tumor cell proliferation and increases apoptosis in Rd76-9 rhabdomyosarcoma tumors. The RCM-1-treated Rd76-9 tumors show reduced FOXM1 staining and decreased expression of proliferation-specific markers Ki67 and PH3. Cleaved caspase staining is increased in the RCM-1 treated tumors, indicating an increase in apoptosis. RCM-1 treatment reduces growth of the B16-FlO melanoma tumors in mice. RCM-1 decreases the B 16-FlO tumor growth as compared to the Vehicle -treated group. RCM-1 treatment decreases tumor cell proliferation and increased apoptosis in B16-FlO melanoma tumors. RCM-1 treatment reduces growth of the human H2122 lung adenocarcinoma in mice[1].
[1]. ARYL SULFONOHYDRAZIDES.WO2018057550A1.
Average Rating: 5
(Based on Reviews and 15 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *